Alkermes Newsroom

Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating

TipRanksOct 27 19:20

Alkermes (ALKS) Gets a Hold From J.P. Morgan

TipRanksOct 26 20:09

Alkermes Is Maintained at Neutral by JP Morgan

Dow JonesOct 25 23:49

Alkermes: Balancing Near-Term Challenges With Long-Term Orexin Market Potential Justifies Hold Rating

TipRanksOct 25 23:17

Alkermes Price Target Cut to $37.00/Share From $38.00 by Piper Sandler

Dow JonesOct 25 23:05

Cantor Fitzgerald Maintains Alkermes(ALKS.US) With Buy Rating, Cuts Target Price to $43

Futu NewsOct 25 22:32

H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $37

Futu NewsOct 25 22:32

BofA Securities Maintains Alkermes(ALKS.US) With Hold Rating

Futu NewsOct 25 22:32

A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $30 to $43

Futu NewsOct 25 21:09

Alkermes (ALKS) Receives a New Rating From Cantor Fitzgerald

TipRanksOct 25 20:29

Alkermes Analyst Ratings

BenzingaOct 25 20:27

HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $37 Price Target

BenzingaOct 25 20:27

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

TipRanksOct 25 19:52

Alkermes: Promising Orexin Developments and Strong Revenue Guidance Support Buy Rating

TipRanksOct 25 00:10

H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $37

Futu NewsOct 14 18:31

Assessing Alkermes' ALKS-2680: A Hold Rating Amidst Potential and Prudence in Sleep Disorder Treatment

TipRanksOct 14 18:17

Analysts Conflicted on These Healthcare Names: Nurix Therapeutics (NRIX) and Alkermes (ALKS)

TipRanksOct 14 16:14

A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $50

Futu NewsOct 11 21:02

Alkermes Price Target Maintained With a $48.00/Share by Cantor Fitzgerald

Dow JonesOct 10 23:18

Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target

BenzingaOct 10 23:09